Register for our free email digests:
Array BioPharma Inc.
Division of Pfizer Inc.
www.arraybiopharma.com
Latest From Array BioPharma Inc.
Biopharma M&A: Lessons From 2019, Trends For 2020
“Growth gaps” were the driver for a record-breaking M&A year – but CEOs must remain disciplined when pursuing opportunities, or pay the price down the line.
Merck To Spin Out A New Company, Following Industry's Downsizing Trend
Merck will spinout its mature franchises, including women's health products, into a new company that will have about $6bn-$6.5bn in 2021 revenues and be poised for modest growth.
2019’s Top Biopharma Deal-Makers
Gene therapy and targeted oncology treatments dominated the biggest acquisitions of the year. Boehringer Ingelheim and Roche were the most active big pharma in-licensers. Cancer and neurology were the focus of most alliances and financings.
Two Mega-Mergers Were Just The Highlights Of A Year Of Major Deals
BMS/Celgene and AbbVie/Allergan were the biggest biopharma deals by dollar value in 2019, and the third and seventh largest ever. The year saw 23 deals valued at $1bn or more, including 20 M&A agreements.
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Cardiovascular
- Infectious & Viral Diseases
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
-
Ron Squarer, CEO
Jason Haddock, CFO
Andrew Robbins, COO
Nicholas A Saccomano, PhD, CSO
Victor Sandor, MD, CMO - Contact Info
-
Array BioPharma Inc.
Phone: (303) 381-6600
3200 Walnut St.
Boulder, CO 80301
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice